Core Insights - Eli Lilly and Company is set to open a new Lilly Gateway Labs site in Philadelphia, enhancing its commitment to fostering biotech innovation in key life sciences hubs [2][3] Company Expansion - The new Gateway Labs site will span 44,000 square feet at 2300 Market, a life sciences facility developed by Breakthrough Properties, providing early-stage biotech companies with fully equipped wet lab facilities and strategic scientific engagement [2] - This expansion in Philadelphia adds to Lilly's existing Gateway Labs locations in Boston, South San Francisco, and San Diego, reinforcing its strategy to establish innovation centers in areas with strong research and entrepreneurial ecosystems [2][3] Biotech Innovation Support - Lilly Gateway Labs is part of the broader Lilly Catalyze360 initiative, which includes Lilly Ventures and other programs aimed at supporting biotech innovation through access to capital, lab space, and advanced research capabilities [3] - Since the inception of the first Gateway Labs site in 2019, resident companies have collectively raised over $3 billion, contributing to the development of more than 50 therapeutic programs [3][5] Industry Context - Philadelphia is recognized as a leading biotech innovation hub, with a history of significant contributions to vaccine development, gene therapy, and Alzheimer's research, making it an ideal location for the new Gateway Labs site [2] - The establishment of the Philadelphia site is expected to catalyze community-building among biotechs, venture partners, and other stakeholders in the life sciences sector [2]

Core Insights - Alexandria Real Estate Equities, Inc. has announced the opening of Lilly Gateway Labs in San Diego, enhancing its collaborative Megacampus ecosystem aimed at biotechnology innovation [1][2][3] Company Overview - Alexandria Real Estate Equities, Inc. is a leading life science real estate investment trust (REIT) with a market capitalization of $25.7 billion and an asset base that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties under construction [5][6] Strategic Collaboration - The Lilly Gateway Labs operates in collaboration with Eli Lilly and Company, integrating Alexandria's real estate infrastructure with Lilly's scientific expertise and venture network [2][3] - This partnership aims to accelerate the development of early-stage biotech companies and foster collaboration between innovative biotechs and large pharmaceutical firms [3] Facility Features - The new Lilly Gateway Labs is located in a LEED Gold certified all-electric laboratory facility, featuring modular lab spaces, advanced scientific tools, and operational support services [4] - The facility is designed to support a diverse range of biotech companies focusing on various disease areas, including Alzheimer's, Parkinson's, cardiovascular diseases, and oncology [4] Ecosystem Development - Alexandria has been instrumental in developing the San Diego life science ecosystem since 1994, positioning the One Alexandria Square Megacampus as a hub for innovation and collaboration [3] - The Megacampus includes amenities such as a café, restaurant, event lawn, and proximity to renowned research institutions, enhancing the ability of tenants to attract and retain talent [3]